Genus Reports First Half 2025 Earnings

Genus (LON:GNS) First Half 2025 Results

Key Financial Results

• Revenue: UK£336.4m (flat on 1H 2024).
• Net income: UK£1.50m (down 89% from 1H 2024).
• Profit margin: 0.4% (down from 4.0% in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genus Earnings Insights

Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are up 2.2% from a week ago.

Valuation

Following the latest earnings results, Genus may be undervalued based on 6 different valuation benchmarks we assess. Click here to view our comprehensive analysis and gain insights into the stock's investment prospects.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.